Heat-shock protein 90 inhibitors in antineoplastic therapy: Is it all wrapped up?

Expert Opinion on Investigational Drugs

Volumn 14, Issue 6, 2005, Pages 569-589

  Isaacs, Jennifer S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

17 (desmethoxy) 17 allylaminogeldanamycin; Akt; Angiogenesis; Chaperone; Combination therapy; ErbB2; Geldanamycin; Hsp90; Hypoxia inducible factor; Renal cancer; Solid tumour; VEGF

Indexed keywords

17 (DESMETHOXY) 17 ALLYLAMINOGELDANAMYCIN; 17 (DIMETHYLAMINOETHYLAMINO) 17 DEMETHOXYGELDANAMYCIN; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 5 AZA 2' DEOXYCYTIDINE; ANGIOGENESIS INHIBITOR; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CHAPERONE; CISPLATIN; DOXORUBICIN; FR 901228; GELDANAMYCIN; GEMCITABINE; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE INHIBITOR; HYPERICIN; HYPOXIA INDUCIBLE FACTOR 1; ICI 101; IMATINIB; LBH 589; MONOCLONAL ANTIBODY DC101; PACLITAXEL; PROTEIN INHIBITOR; RADIOSENSITIZING AGENT; TAMOXIFEN; UNCLASSIFIED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CELL VIABILITY; CLEAR CELL CARCINOMA; CLINICAL TRIAL; CYTOTOXICITY; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; KIDNEY CARCINOMA; LIVER TOXICITY; NONHUMAN; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STRESS;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASMS;

EID: 21244446219     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.6.569     Document Type: Review

References (186)

1. PICARD D, KHURSHEED B, GARABEDIAN MJ et al.: Reduced levels of hsp90 compromise steroid receptor action in vivo. Nature (1990) 348(6297):166-168.
2. BOHEN SP, YAMAMOTO KR: Isolation of Hsp90 mutants by screening for decreased steroid receptor function. Proc. Natl. Acad. Sci. USA (1993) 90(23):11424-11428.
3. XU Y, LINDQUIST S: Heat-shock protein hsp90 governs the activity of pp60v-src kinase. Proc. Natl. Acad. Sci. USA (1993) 90(15):7074-7078.
4. WHITESELL L, MIMNAUGH EG, DE COSTA B, MYERS CE, NECKERS LM: Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA (1994) 91(18):8324-8328.
5. BLAGOSKLONNY MV, TORETSKY J, BOHEN S, NECKERS L: Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc. Natl. Acad. Sci. USA (1996) 93(16):8379-8383.
6. AN WG, SCHULTE TW, NECKERS LM: The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. (2000) 11(7):355-360.
7. BONVINI P, GASTALDI T, FALINI B, ROSOLEN A: Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Res. (2002) 62(5):1559-1566.
8. CSERMELY P, SCHNAIDER T, SOTI C, PROHASZKA Z, NARDAI G: The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol. Ther. (1998) 79(2):129-168.
9. MALONEY A, WORKMAN P: HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. (2002) 2(1):3-24.
10. ISAACS JS, XU W, NECKERS L: Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell (2003) 3(3):213-217.
11. PRODROMOU C, ROE SM, O'BRIEN R et al.: Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell (1997) 90(1):65-75.
12. MARCU MG, CHADLI A, BOUHOUCHE I, CATELLI M, NECKERS LM: The heat shock protein-90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. (2000) 275(47):37181-37186.
13. OBERMANN WM, SONDERMANN H, RUSSO AA, PAVLETICH NP, HARTL FU: In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J. Cell Biol. (1998) 143(4):901-910.
14. PRODROMOU C, PANARETOU B, CHOHAN S et al.: The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains. EMBO. J. (2000) 19(16):4383-4392.
15. PRODROMOU C, SILIGARDI G, O'BRIEN R et al.: Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones. EMBO. J. (1999) 18(3):754-762.
16. YOUNG JC, HARTL FU: Polypeptide release by Hsp90 involves ATP hydrolysis and is enhanced by the co-chaperone p23. EMB0. J. (2000) 19(21):5930-5940.
17. PANARETOU B, SILIGARDI G, MEYER P et al.: Activation of the ATPase activity of hsp90 by the stress-rcgulated cochaperone aha1. Mol. Cell. (2002) 10(6):1307-1318.
18. SILIGARDI G, PANARETOU B, MEYER P et al.: Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50cdc37. J. Biol. Chem. (2002) 277(23):20151-20159.
19. GRENERT JP, SULLIVAN WP, FADDE P et al.: The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J. Biol. Chem. (1997) 272(38):23843-23850.
20. SULLIVAN W, STENSGARD B, CAUCUTT G et al.: Nucleotides and two functional states of hsp90. J. Biol. Chem. (1997) 272(12):8007-8012.
21. WHITESELL L, SHIFRIN SD, SCHWAB G, NECKERS LM: Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res. (1992) 52(7):1721-1728.
22. STEBBINS CE, RUSSO AA, SCHNEIDER C et al.: Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell (1997) 89(2):239-250.
23. SCHNEIDER C, SEPP-LORENZINO L, NIMMESGERN E et al.: Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc. Natl. Acad. Sci. USA (1996) 93(25):14536-14541.
24. HOHFELD J, CYR DM, PATTERSON C: From the cradle to the grave: molecular chaperones that may choose between folding and degradation. EMBO Rep. (2001) 2(10):885-890.
25. NECKERS L: Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. (2002) 8(4 Suppl.):S55-S61.
26. NECKERS L: Heat shock protein 90 inhibition by 17-allylamino-17-demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer. Clin. Cancer Res. (2002) 8(5):962-966.
27. KELLAND LR, SHARP SY, ROGERS PM, MYERS TG, WORKMAN P: DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. (1999) 91(22):1940-1949.
28. SOLIT DB, ZHENG FF, DROBNJAK M et al.: 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res. (2002) 8(5):986-993.
29. EGORIN MJ, LAGATTUTA TF, HAMBURGER DR et al.: Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother. Pharmacol. (2002) 49(1):7-19.
30. BELIAKOFF J, WHITESELL L: Hsp90: an emerging target for breast cancer therapy. Anticancer Drugs (2004) 15(7):651-662.
31. DYMOCK BW, DRYSDALE MJ, McDONALD E, WORKMAN P: Inhibitors of Hsp90 and other chaperones for the treatment of cancer. Expert Opin. Ther. Patents (2004) 14(6):837-847.
32. GORRE ME, ELLWOOD-YEN K, CHIOSIS G, ROSEN N, SAWYERS CL: BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood (2002) 100(8):3041-3044.
33. ZEGARRA-MORO OL, SCHMIDT LJ, HUANG H, TINDALL DJ: Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res. (2002) 62(4):1008-1013.
34. SHAH NP, NICOLL JM, NAGAR B et al.: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI-571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 2(2):117-125.
35. GEORGE P, BALI P, ANNAVARAPU S et al.: Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood (2005) 105(4):1768-1776.
36. SLAMON DJ, CLARK GM, WONG SG et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 235(4785):177-182.
37. ZHONG H, DE MARZO AM, LAUGHNER E et al.: Overexpression of hypoxia-inducible factor 1-α in common human cancers and their metastases. Cancer Res. (1999) 59(22):5830-5835.
38. BACUS SS, ALTOMARE DA, LYASS L et al.: AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene (2002) 21(22):3532-3540.
39. SCHINDL M, SCHOPPMANN SF, SAMONIGG H et al.: Overexpression of hypoxia-inducible factor 1-α is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin. Cancer Res. (2002) 8(6):1831-1837.
40. MIMNAUGH EG, CHAVANY C, NECKERS L: Polyubiquitination and proteasomal degradation of the p185c-ErbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem. (1996) 271(37):22796-22801.
41. BASSO AD, SOLIT DB, CHIOSIS G et al.: Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J. Biol. Chem. (2002) 277(42):39858-39866.
42. ISAACS JS, JUNG YJ, MIMNAUGH EG et al.: Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1-α-degradative pathway. J. Biol. Chem. (2002) 277(33):29936-29944.
43. MABJEESH NJ, POST DE, WILLARD MT et al.: Geldanamycin induces degradation of hypoxia-inducible factor 1-α protein via the proteosome pathway in prostate cancer cells. Cancer Res. (2002) 62(9):2478-2482.
44. HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 86(3):353-364.
45. FOLKMAN J, KLAGSBRUN M: Angiogenic factors. Science (1987) 235(4787):442-447.
46. FERRARA N, ALITALO K: Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. (1999) 5(12):1359-1364.
47. FERRARA N, HILLAN KJ, GERBER HP, NOVOTNY W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. (2004) 3(5):391-400.
48. RINI BI, SMALL EJ: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J. Clin. Oncol. (2005) 23(5):1028-1043.
49. COOK JA, GIUS D, WINK DA et al.: Oxidative stress, redox, and the tumor microenvironment. Semin. Radiat. Oncol. (2004) 14(3):259-266.
50. MOELLER BJ, CAO, Y, LI CY, DEWHIRST MW: Radiation activates HIF-1 to regulate vascular radiosensitiviry in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell (2004) 5(5):429-441.
51. SEMENZA GL: Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer (2003) 3(10):721-732.
52. BIRNER P, SCHINDL M, OBERMAIR A et al.: Overexpression of hypoxia-inducible factor 1-α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. (2000) 60(17):4693-4696.
53. TALKS KL, TURLEY H, GATTER KC et al.: The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2-α in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. (2000) 157(2):411-421.
54. IWAI K, YAMANAKA K, KAMURA T et al.: Identification of the von Hippellindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc. Natl. Acad. Sci. USA (1999) 96(22):12436-12441.
55. MAXWELL PH, WIESENER MS, CHANG GW et al.: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 399(6733):271-275.
56. OHH M, PARK CW, IVAN M et al.: Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nat. Cell Biol. (2000) 2(7):423-427.
57. BRUICK RK, McKNIGHT SL: A conserved family of prolyl-4-hydroxylases that modify HIF. Science (2001) 294(5545):1337-1340.
58. EPSTEIN AC, GLEADLE JM, McNEILL LA et al.: C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell (2001) 107(1):43-54.
59. 2 sensing. Science (2001) 292(5516):464-468.
60. 2-regulated prolyl hydroxylation. Science (2001) 292(5516):468-472.
61. MEKHAIL K, GUNARATNAM L, BONICALZI ME, LEE S: HIF activation by pH-dependent nucleolar sequestration of VHL. Nat Cell Biol (2004) 6(7):642-647.
62. WARBURG O: On the origin of cancer cells. Science (1956) 123:309-314.
63. LATIF F, TORY K, GNARRA J et al.: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (1993) 260(5112):1317-1320.
64. GNARRA JR, TORY K, WENG Y et al.: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. (1994) 7(1):85-90.
65. HERMAN JG, LATIF F, WENG Y et al.: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA (1994) 91(21):9700-9704.
66. WIESENER MS, MUNCHENHAGEN PM, BERGER I et al.: Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1α in clear cell renal carcinomas. Cancer Res. (2001) 61(13):5215-5222.
67. ILIOPOULOS O, KIBEL A, GRAY S, KAELIN WG Jr.: Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. (1995) 1(8):822-826.
68. ILIOPOULOS O, LEVY AP, JIANG C, KAELIN WG Jr., GOLDBERG MA: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA (1996) 93(20):10595-10599.
69. KAELIN WG Jr.: Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer (2002) 2(9):673-682.
70. KONDO K, KLCO J, NAKAMURA E, LECHPAMMER M, KAELIN WG Jr.: Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell (2002) 1(3):237-246.
71. MARANCHIE JK, VASSELLI JR, RISS J et al.: The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell (2002) 1(3):247-255.
72. GERALD D, BERRA E, FRAPART YM et al.: JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell (2004) 118(6):781-794.
73. 2 for platelet-derived growth factor signal transduction. Science (1995) 270(5234):296-299.
74. YOON SO, PARK SJ, YOON SY, YUN CH, CHUNG AS: Sustained production of H(2)O(2) activates promatrix metalloproteinase-2 through receptor tyrosine kinases/phosphatidylinositol 3-kinase/NF-κB pathway. J. Biol. Chem. (2002) 277(33):30271-30282.
75. SELAK MA, ARMOUR SM, MacKENZIE ED et al.: Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell (2005) 7(1):77-85.
76. LAUGHNER E, TAGHAVI P, CHILES K, MAHON PC, SEMENZA GL: HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. (2001) 21(12):3995-4004.
77. BLACKWELL KL, DEWHIRST MW, LIOTCHEVA V et al.: HER-2 gene amplificanion correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clin. Cancer Res. (2004) 10(12 Part 1):4083-4088.
78. BECKERS J, HERRMANN F, RIEGER S et al.: Identification and validation of novel ERBB2 (HER2, NEU)targets including genes involved in angiogencsis. Int. J. Cancer (2005) 114(4):590-597.
79. BOS R, VAN DIEST PJ, DE JONG JS et al.: Hypoxia-inducible factor-1α is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology (2005) 46(1):31-36.
80. GRADIN K, McGUIRE J, WENGER RH et al.: Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor. Mol. Cell. Biol. (1996) 16(10):5221-5231.
81. KUREBAYASHI J, OTSUKI T, KUROSUMI M et al.: A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1α and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts. Jpn. J. Cancer Res. (2001) 92(12):1342-1351.
82. LEBEAU J, LE CHALONY C, PROSPERI MT, GOUBIN G: Constitutive overexpression of a 89 kDa heat shock protein gene in the HBL100 human mammary cell fine converted to a tumorigenic phenotype by the EJ/T24 Harvey-ras oncogene. Oncogene (1991) 6(7):1125-1132.
83. FERRARINI M, HELTAI S, ZOCCHI MR, RUGARLI C: Unusual expression and localization of heat-shock proteins in human tumor cells. Int. J. Cancer (1992) 51(4):613-619.
84. NIMMANAPALLI R, O'BRYAN E, BHALLA K: Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Ab1-positive human leukemic blasts. Cancer Res. (2001) 61(5):1799-1804.
85. VISAKORPI T, HYYTINEN E, KOIVISTO P et al.: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. (1995) 9(4):401-406.
86. FANG Y, FLISS AE, ROBINS DM, CAPLAN AJ: Hsp90 regulates androgen receptor hormone binding affinity in vivo. J. Biol. Chem. (1996) 271(45):28697-28702.
87. VANAJA DK, MITCHELL SH, TOFT DO, YOUNG CY: Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones (2002) 7(1):55-64.
88. WEINSTEIN IB: Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science (2002) 297(5578):63-64.
89. NGUYEN DM, DESAI S, CHEN A, WEISER TS, SCHRUMP DS: Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin. Ann. Thorac. Surg. (2000) 70(6):1853-1860.
90. DUDA DG, FUKUMURA D, JAIN RK: Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol. Med. (2004) 10(4):143-145.
91. SHI Y, BAKER JE, ZHANG C et al.: Chronic hypoxia increases endothelial nitric oxide synthase generation of nitric oxide by increasing heat shock protein 90 association and serine phosphorylation. Circ. Res. (2002) 91(4):300-306.
92. BROUET A, SONVEAUX P, DESSY C et al.: Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ. Res. (2001) 89(10):866-873.
93. FONTANA J, FULTON D, CHEN Y et al.: Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ. Res. (2002) 90(8):866-873.
94. DIMMELER S, FLEMING I, FISSLTHALER B et al.: Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature (1999) 399(6736):601-605.
95. THOMAS DD, ESPEY MG, RIDNOUR LA et al.: Hypoxic inducible factor 1α, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc. Natl. Acad. Sci. USA (2004) 101(24):8894-8899.
96. TAKAHASHI S, MENDELSOHN ME: Calmodulin-dependent and -independent activation of endothelial nitric-oxide synthase by heat shock protein 90. J. Biol. Chem. (2003) 278(11):9339-9344.
97. YEN L, BENLIMAME N, NIE ZR et al.: Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol. Biol. Cell (2002) 13(11):4029-4044.
98. LOUREIRO RM, MAHARAJ AS, DANKORT D, MULLER WJ, D'AMORE PA: ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter. Biochem. Biophys. Res. Commun. (2005) 326(2):455-465.
99. LE BOEUF F, HOULE F, HUOT J: Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. J. Biol. Chem. (2004) 279(37):39175-39185.
100. KAUR G, BELOTTI D, BURGER AM et al.: Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin. Cancer Res. (2004) 10(14):4813-4821.
101. OCHEL HJ, SCHULTE TW, NGUYEN P, TREPEL J, NECKERS L: The benzoquinone ansamycin geldanamycin stimulates proteolytic degradation of focal adhesion kinase. Mol. Genet. Metab. (1999) 66(1):24-30.
102. ROUSSEAU S, HOULE F, KOTANIDES H et al.: Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J. Biol. Chem. (2000) 275(14):10661-10672.
103. WEBB CP, HOSE CD, KOOCHEKPOUR S et al.: The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-meturokinase plasminogen acrivator-plasmin proteolytic network. Cancer Res. (2000) 60(2):342-349.
104. KAMAL A, THAO L, SENSINTAFFAR J et al.: A high-affinity conformation of Hsp90 confers rumour selectivity on Hsp90 inhibitors. Nature (2003) 425(6956):407-410.
105. CHIOSIS G, HUEZO H, ROSEN N et al.: 17AAG: low target binding affinity and potent cell activity-finding an explanation. Mol. Cancer Ther. (2003) 2(2):123-129.
106. VILENCHIK M, SOLIT D, BASSO A et al.: Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem. Biol. (2004) 11(6):787-797.
107. BECKER B, MULTHOFF G, FARKAS B et al.: Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp. Dermatol. (2004) 13(1):27-32.
108. EUSTACE BK, SAKURAI T, STEWART JK et al.: Functional proteomic screens reveal an essential extracellular role for hsp90α in cancer cell invasiveness. Nat. Cell Biol. (2004) 6(6):507-514.
109. EUSTACE BK, JAY DG: Extracellular roles for the molecular chaperone, hsp90. Cell Cycle (2004) 3(9):1098-1100.
110. SIDERA K, SAMIOTAKI M, YFANTI E, PANAYOTOU G, PATSAVOUDI E: Involvement of cell surface HSP90 in cell migration reveals a novel role in the developing nervous system. J. Biol. Chem. (2004) 279(44):45379-45388.
111. KENDEROV A, MINKOVA V, MIHAILOVA D et al.: Lupus-specific kidney deposits of HSP90 are associated with altered IgG idiotypic interactions of anti-HSP90 autoantibodies. Clin. Exp. Immunol. (2002) 129(1):169-176.
112. VIDAL CI, MINTZ PJ, LU K et al.: An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. Oncogene (2004) 23(55):8859-8867.
113. BINDER RJ, BLACHERE NE, SRIVASTAVA PK: Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J. Biol. Chem. (2001) 276(20):17163-17171.
114. LEES-MILLER SP, ANDERSON CW: The human double-stranded DNA-activated protein kinase phosphorylares the 90-kDa heat-shock protein, hsp90α at two NH2-terminal threonine residues. J. Biol. Chem. (1989) 264(29):17275-17280.
115. MIMNAUGH EG, WORLAND PJ, WHITESELL L, NECKERS LM: Possible role for serine/threonine phosphorylation in the regulation of the heteroprotein complex between the hsp90 stress protein and the pp60v-src tyrosine kinase. J. Biol. Chem. (1995) 270(48):28654-28659.
116. MIYATA Y, YAHARA I: Interaction between casein kinase II and the 90-kDa stress protein, HSP90. Biochemistry (1995) 34(25):8123-8129.
117. ZHAO YG, GILMORE R, LEONE G et al.: Hsp90 phosphorylation is linked to its chaperoning function. Assembly of the reovirus cell attachment protein. J. Biol. Chem. (2001) 276(35):32822-32827.
118. OGISO H, KAGI N, MATSUMOTO E et al.: Phosphorylation analysis of 90 kDa heat shock protein within the cytosolic arylhydrocarbon receptor complex. Biochemistry (2004) 43(49):15510-15519.
119. NAKAJIMA H, KIM YB, TERANO H, YOSHIDA M, HORINOUCHI S: FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. (1998) 241(1):126-133.
120. MARKS PA, RICHON VM, RIFKIND RA: Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. (2000) 92(15):1210-1216.
121. YU X, GUO ZS, MARCU MG et al.: Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl Cancer Inst. (2002) 94(7):504-513.
122. ATADJA P, HSU M, KWON P et al.: Molecular and cellular basis for the antiproliferative effects of the HDAC inhibitor LAQ824. Novartis Found Symp (2004) 259:249-266 (Discussion 266-248 and 285-248).
123. FUJIWARA H, YAMAKUNI T, UENO M et al.: IC101 induces apoptosis by Akt dephosphorylation via an inhibition of heat shock protein 90-ATP binding activity accompanied by preventing the interaction with Akt in L1210 cells. J. Pharmacol. Exp. Ther. (2004) 310(3):1288-1295.
124. LI M, BROOKS CL, WU-BAER F et al.: Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science (2003) 302(5652):1972-1975.
125. JASON LJ, FINN RM, LINDSEY G, AUSIO J: Histone H2A ubiquitination does not preclude histone H1 binding, but it facilitates its association with the nucleosome. J. Biol. Chem. (2005) 280(6):4975-4982.
126. BLANK M, MANDEL M, KEISARI Y, MERUELO D, LAVIE G: Enhanced ubiquitinylation of heat shock protein 90 as a potential mechanism for mitotic cell death in cancer cells induced with hypericin. Cancer Res. (2003) 63(23):8241-8247.
127. SHAO J, PRINCE T, HARTSON SD, MATTS RL: Phosphorylation of serine 13 is required for the proper function of the Hsp90 co-chaperone, Cdc37. J. Biol. Chem. (2003) 278(40):38117-38120.
128. MIYATA Y, NISHIDA E: CK2 controls multiple protein kinases by phosphorylating a kinase-targeting molecular chaperone, Cdc37. Mol. Cell. Biol. (2004) 24(9):4065-4074.
129. XU X, LANDESMAN-BOLLAG E, CHANNAVAJHALA PL, SELDIN DC: Murine protein kinase CK2: gene and oncogene. Mol. Cell. Biochem. (1999) 191(1-2):65-74.
130. PIEKARZ RL, ROBEY R, SANDOR V et al.: Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood (2001) 98(9):2865-2868.
131. SANDOR V, BAKKE S, ROBEY RW et al.: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. (2002) 8(3):718-728.
132. KELLY WK, RICHON VM, O'CONNOR O et al.: Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. (2003) 9(10 Part 1):3578-3588.
133. WEISER TS, OHNMACHT GA, GUO ZS et al.: Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann. Thorac. Surg. (2001) 71(1):295-301 (Discussion 301-292).
134. RAHMANI M, YU C, DAI Y et al.: Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res. (2003) 63(23):8420-8427.
135. ADAMS J: The development of proteasome inhibitors as anticancer drugs. Cancer Cell (2004) 5(5):417-421.
136. PAPANDREOU CN, LOGOTHETIS CJ: Bortezomib as a potential treatment for prostate cancer. Cancer Res. (2004) 64(15):5036-5043.
137. ORLOWSKI RZ, STINCHCOMBE TE, MITCHELL BS et al.: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. (2002) 20(22):4420-4427.
138. MIMNAUGH EG, XU W, VOS M et al.: Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol. Cancer Ther. (2004) 3(5):551-566.
139. HENNESSY BT, GARCIA-MANERO G, KANTARJIAN HM, GILES FJ: DNA methylation in haematological malignancies: the role of decitabine. Expert Opin. Investig. Drugs (2003) 12(12):1985-1993.
140. MOMPARLER RL, ONETTO N, MOMPARLER LF et al.: Drug sensitivity test for patients with acute leukemia on high-dose ara-C therapy. Semin. Oncol. (1985) 12(2 Suppl. 3):31-33.
141. ALLEMAN WG, TABIOS RL, CHANDRAMOULI GV et al.: The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2′-deoxycytidine. Clin. Cancer Res. (2004) 10(20):7011-7021.
142. HAMAMOTO R, FURUKAWA Y, MORITA M et al.: SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat. Cell Biol. (2004) 6(8):731-740.
143. BULL EE, DOTE H, BRADY KJ et al.: Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin. Cancer Res. (2004) 10(23):8077-8084.
144. BISHT KS, BRADBURY CM, MATTSON D et al.: Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res. (2003) 63(24):8984-8995.
145. ENMON R, YANG WH, BALLANGRUD AM et al.: Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer Res. (2003) 63(23):8393-8399.
146. MACHIDA H, MATSUMOTO Y, SHIRAI M, KUBOTA N: Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation. Int. J. Radiat. Biol. (2003) 79(12):973-980.
147. RUSSELL JS, BURGAN W, OSWALD KA, CAMPHAUSEN K, TOFILON PJ: Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin. Cancer Res. (2003) 9(10 Part 1):3749-3755.
148. BARTEK J, LUKAS J: Chk1 and Chk2 kinases in checkpoint control and cancer: Cancer Cell (2003) 3(5):421-429.
149. SORENSEN CS, HANSEN LT, DZIEGIELEWSKI J et al.: The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat. Cell Biol. (2005) 7(2):195-201.
150. ARLANDER SJ, EAPEN AK, VROMAN BT et al.: Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J. Biol. Chem. (2003) 278(52):52572-52577.
151. ALTIERI DC: Coupling apoptosis resistance to the cellular stress response: the IAP-Hsp90 connection in cancer. Cell Cycle (2004) 3(3):255-256.
152. BURROWS F, ZHANG H, KAMAL A: Hsp90 activation and cell cycle regulation. Cell Cycle (2004) 3(12):1530-1536.
153. BLAGOSKLONNY MV, FOJO T, BHALLA KN et al.: The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia (2001) 15(10):1537-1543.
154. BAGATELL R, WHITESELL L: Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol. Cancer Ther. (2004) 3(8):1021-1030.
155. MUNSTER PN, BASSO A, SOLIT D, NORTON L, ROSEN N: Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res. (2001) 7(8):2228-2236.
156. DONG J, GRUNSTEIN J, TEJADA M et al.: VEGF-null cells require PDGFR-α signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J. (2004) 23(14):2800-2810.
157. RELF M, LEJEUNE S, SCOTT PA et al.: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. (1997) 57(5):963-969.
158. SAKAGAMI M, MORRISON P, WELCH WJ: Benzoquinoid ansamycins (herbimycin A and geldanamycin) interfere with the maturation of growth factor receptor tyrosine kinases. Cell Stress Chaperones (1999) 4(1):19-28.
159. DE CANDIA P, SOLIT DB, GIRI D et al.: Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proc. Natl. Acad. Sci. USA (2003) 100(21):12337-12342.
160. CHAE SS, PAIK JH, FURNEAUX H, HLA T: Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J. Clin. Invest. (2004) 114(8):1082-1089.
161. DUXBURY MS, MATROS E, ITO H et al.: Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer. Ann. Surg. (2004) 240(4):667-674 (Discussion 675-666).
162. CHUNG YL, TROY H, BANERJI U et al.: Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J. Natl Cancer Inst. (2003) 95(21):1624-1633.
163. SMITH-JONES PM, SOLIT DB, AKHURST T et al.: Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat. Biotechnol. (2004) 22(6):701-706.
164. WILLETT CG, BOUCHER Y, DI TOMASO E et al.: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 10(2):145-147.
165. SHAKED Y, BERTOLINI F, MAN S et al.: Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell (2005) 7(1):101-111.
166. MILLER JC, PIEN HH, SAHANI D, SORENSEN AG, THRALL JH: Imaging angiogenesis: applications and potential for drug development. J.
167. REHMAN S, JAYSON GC: Molecular imaging of antiangiogenic agents. Oncologist (2005) 10(2):92-103.
168. THOMPSON JE, THOMPSON CB: Putting the rap on Akt. J. Clin. Oncol. (2004) 22(20):4217-4226.
169. SEAGROVES TN, RYAN HE, LU H et al.: Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol. Cell. Biol. (2001) 21(10):3436-3444.
170. MANKOFF DA, DEHDASHTI F, SHIELDS AF: Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia (2000) 2(1-2):71-88.
171. CALABRESE C, FRANK A, MacLEAN K, GILBERTSON R: Medulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK/ERKM. J. Biol. Chem. (2003) 278(27):24951-24959.
172. MUNSTER PN, MARCHION DC, BASSO AD, ROSEN N: Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res. (2002) 62(11):3132-3137.
173. VASILEVSKAYA IA, RAKITINA TV, O'DWYER PJ: Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell fines. Mol. Pharmacol. (2004) 65(1):235-243.
174. BELIAKOFF J, BAGATELL R, PAINE-MURRIETA G et al.: Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin. Cancer Res. (2003) 9(13):4961-4971.
175. ISAACS JS, JUNG YJ, NECKERS L: Aryl hydrocarbon nuclear translocator (ARNT) promotes oxygen-independent stabilization of hypoxia-inducible factor-1α by modulating an Hsp90-dependent regulatory pathway. J. Biol. Chem. (2004) 279(16):16128-16135.
176. DE CARCER G: Heat shock protein 90 regulates the metaphase-anaphase transition in a polo-like kinase-dependent manner. Cancer Res. (2004) 64(15):5106-5112.
177. WINKLER F, KOZIN SV, TONG RT et al.: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell (2004) 6(6):553-563.
178. BANERJI U, JUDSON I, WORKMAN P: The clinical applications of heat shock protein inhibitors in cancer - present and future. Curr. Cancer Drug Targets (2003) 3(5):385-390.
179. MEARES GP, ZMIJEWSKA AA, JOPE RS: Heat shock protein-90 dampens and directs signaling stimulated by insulin-like growth factor-1 and insulin. FEBS Lett. (2004) 574(1-3):181-186.
180. CITRI A, GAN J, MOSESSON Y et al.: Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep. (2004) 5(12):1165-1170.
181. KATSCHINSKI DM, LE L, HEINRICH D et al.: Heat induction of the unphosphorylated form of hypoxia-inducible factor-1α is dependent on heat shock protein-90 activity. J. Biol. Chem. (2002) 277(11):9262-9267.
182. NECKERS L, IVY SP: Heat shock protein 90. Curr. Opin. Oncol. (2003) 15(6):419-424.
183. BRANNON-PEPPAS L, BLANCHETTE JO: Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. (2004) 56(11):1649-1659.
184. KUNG AL, ZABLUDOFF SD, FRANCE DS et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell (2004) 6(1):33-43.
185. HOOD L, HEATH JR, PHELPS ME, LIN B: Systems biology and new technologies enable predictive and preventative medicine. Science (2004) 306(5696):640-643.
186. KOHN KW, RISS J, APRELIKOVA O et al.: Properties of switch-like bioregulatory networks studied by simulation of the hypoxia response control system. Mol. Biol. Cell (2004) 15(7):3042-3052.